| WARF: P00352US |  |
| 2-Ethyl and 2-Ethylidene-19-Nor-Vitamin D Compounds |
| INVENTORS | • | Hector DeLuca, Rafal Sicinski |
The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing biologically active 19-nor-vitamin D analogs that may be useful for the treatment of metabolic bone diseases and other disorders.
OVERVIEW
Vitamin D is a highly potent regulator of calcium homeostasis and plays a role in cellular differentiation. A recently discovered class of vitamin D analogs, the 19-nor-vitamin D compounds, displays a selective activity profile of high cellular differentiation activity and very low calcium mobilizing activity. This profile makes these compounds potentially useful for treating various disorders.
THE INVENTION
UW-Madison researchers have developed biologically active 19-nor-vitamin D analogs substituted at C-2 in the A-ring with an ethylidene or an ethyl group. These compounds are highly specific in their calcemic activity. Their preferential activity in mobilizing calcium from bone, and either high or normal intestinal calcium transport activity, allows their in vivo administration for treating metabolic bone diseases where bone loss is a major concern. These compounds are also characterized by high cell differentiation activity, suggesting their use as anti-cancer agents.
APPLICATIONS
- Potentially useful as anti-cancer agents, particularly against leukemia, colon cancer, breast cancer and prostate cancer
- Promising therapeutic agents for treatment of diseases where bone formation is desired, such as osteoporosis, osteomalacia and renal osteodystrophy
- May also be useful for hastening bone fracture healing and improving bone grafts
- Especially useful for treatment of immune disorders, including multiple sclerosis, lupis, diabetes mellitus, host versus graft reaction and organ transplant rejection
- Prospective treatment for inflammatory diseases such as rheumatoid arthritis, asthma and inflammatory bowel diseases
- May be useful for the treatment of skin conditions such as psoriasis, dermatitis, eczema, keratosis, wrinkles, slack skin, dry skin and insufficient sebum secretion
- Potential treatment for other disorders including acne, alopecia, hypertension, hypocalcemia and hypoparathyroidism
KEY BENEFITS
- Potentially useful for the treatment of various disorders
- Compounds may be administered orally, topically, parenterally, sublingually, intranasally or transdermally.
ADDITIONAL INFORMATION
For More Information About the Inventors
Intellectual Property Status
Tech Fields
Pharmaceuticals & Vitamin D - Musculoskeletal
Pharmaceuticals & Vitamin D - Skin & connective tissue
Pharmaceuticals & Vitamin D - Vitamin D
CONTACT INFORMATION
For current licensing status, please contact our team at
licensing@warf.org
or phone 608.262.4924. (Clicking this link will open a contact form in a popup window. If you have problems viewing the form, try disabling your popup blocker software.)
WARF: A Leader in Technology Transfer Since 1925
Since its founding as the patenting and licensing arm of the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.
The University of Wisconsin and WARF -
A Single Location to Accelerate Translational Development of New Drugs
The UW-Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities in the country, UW-Madison offers state-of-the-art facilities unmatched by most public universities.
These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW-Madison with a complete translational research facility; and soon, the Wisconsin Institutes for Discovery, made up of innovative private and public interdisciplinary biomedical research institutes. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.
Since its founding as the patenting and licensing arm of the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.
The University of Wisconsin and WARF -
A Single Location to Accelerate Translational Development of New Drugs
The UW-Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities in the country, UW-Madison offers state-of-the-art facilities unmatched by most public universities.
These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW-Madison with a complete translational research facility; and soon, the Wisconsin Institutes for Discovery, made up of innovative private and public interdisciplinary biomedical research institutes. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.
